Situation: A nurse at a Rural Health Unit (RHU) trained in the World Health Organization Mental Health Gap Action Programme Intervention Guide (mhGAP-IG) follows up a 24-year-old woman who has just been diagnosed with epilepsy and started on carbamazepine. She lives with her husband and works as a store clerk. Over 4 months of follow-up, she takes her tablets as prescribed, and the nurse records one new finding at each visit. According to mhGAP-IG, which finding calls for switching to a different antiepileptic medicine rather than adjusting the dose?

mhGAP-IG treats drowsiness, nystagmus, double vision, and unsteadiness as adverse effects of a dose that is too high, managed by adjusting the dose, while idiosyncratic reactions such as allergy, bone marrow depression, or hepatic failure require switching the medicine. Jaundice with dark urine suggests liver injury, an idiosyncratic reaction. A reduction in seizures of less than 50% in an adherent person first calls for raising the dose toward the maximum; switching is considered only if response is still poor.

Core mhGAP-IG decision logic

The key distinction in this question is between dose-dependent adverse effects and idiosyncratic reactions. Carbamazepine can cause both, but they are managed very differently.

Dose-dependent effects such as drowsiness, nystagmus, double vision, and unsteadiness reflect a dose that is too high for that person and are managed by reducing or adjusting the dose. In contrast, idiosyncratic reactions such as allergy, bone marrow depression, or hepatic failure are unpredictable and require switching to a different antiepileptic medicine.

Key point! The finding of yellow sclerae with dark urine points to jaundice and bilirubinuria, which signal liver injury. This is an idiosyncratic reaction, not a dose-related effect, so the correct action is to change the medicine.

Watch out! A seizure reduction of only 40% in a person who is adherent first calls for raising the dose toward the maximum. Switching is considered only if the response remains poor after the dose has been optimized.

Finding	Classification	mhGAP-IG action
Seizure frequency reduced by 40%	Suboptimal therapeutic response	Increase dose toward maximum first; switch only if still poor
Drowsiness in first week	Dose-dependent adverse effect (early, often transient)	Adjust dose; may resolve with time
Double vision after dose increase	Dose-dependent adverse effect (toxicity)	Reduce or adjust dose
Yellow sclerae with dark urine	Idiosyncratic reaction (hepatic injury)	Switch to a different antiepileptic medicine

Why liver injury means switching, not dose adjustment

Antiseizure medication-related liver injury is a well-recognized concern in epilepsy care. Most cases are idiosyncratic, meaning they arise from unpredictable hypersensitivity or immune-mediated mechanisms rather than from the pharmacological dose itself ^[1]. This is fundamentally different from toxicity that tracks with drug concentration.

The clinical picture of yellow sclerae and dark urine reflects conjugated hyperbilirubinemia spilling into the urine. In the context of carbamazepine, this should raise concern for hepatocellular injury. Idiosyncratic drug-induced liver injury encompasses several immune-mediated phenotypes, including drug-induced autoimmune hepatitis and hypersensitivity-driven reactions . The unifying principle is that continuing the offending drug can allow progression to life-threatening liver failure.

Key point! In idiosyncratic reactions, the liver injury is not proportional to the dose. Reducing the carbamazepine dose will not reliably stop the immune-mediated damage, so the mhGAP-IG directs switching to a different antiepileptic medicine.

The broader hypersensitivity spectrum reinforces this concern. DRESS syndrome, a severe drug hypersensitivity reaction, can present with jaundice, acute liver failure, and multiorgan involvement . Although DRESS is rare, the presence of jaundice in a person taking carbamazepine warrants immediate recognition that this is not a simple dose-toxicity problem.

Why the other options are dose-related

Drowsiness in the first week is a common, typically transient dose-dependent effect when starting carbamazepine. It often improves as tolerance develops, and mhGAP-IG manages it by adjusting the dose or timing rather than switching.

Double vision after a dose increase is a classic sign of carbamazepine neurotoxicity. Diplopia, along with nystagmus and ataxia, correlates with elevated drug levels and resolves when the dose is lowered.

A 40% seizure reduction indicates partial response. Since the person is adherent, the logical next step is to increase the dose toward the maximum tolerated or recommended level. Only after an adequate trial at optimized dosing would switching be considered.

The decision rule is: dose-dependent effects are corrected by dose adjustment, while idiosyncratic reactions such as hepatic injury require changing the medicine. Jaundice with dark urine is the only option that falls into the idiosyncratic category.